<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01424787</url>
  </required_header>
  <id_info>
    <org_study_id>RP-OSV-01-EU</org_study_id>
    <nct_id>NCT01424787</nct_id>
  </id_info>
  <brief_title>Non-interventional Study to Evaluate the Ease of Reaching Individual Goals in Serum Phosphorus (Steering)</brief_title>
  <acronym>Steering</acronym>
  <official_title>Non-interventional Study to Evaluate the Ease of Reaching Individual Goals in Serum Phosphorus (Steering)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fresenius Medical Care Deutschland GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Siro Clinpharm Germany GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Fresenius Medical Care Deutschland GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this non-interventional study is to confirm that with standard OsvaRen®
      treatment it is possible to achieve in at least 60% of the patients the levels of phosphorus,
      total calcium, and iPTH seen in the CALMAG study also in the normal clinical practice.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Only a small fraction of haemodialysis patients meet the published NKF-KDOQI standards for
      calcium, phosphorus, calcium x phosphorus product and intact parathyroid hormone. One of the
      reasons is the still difficult and insufficient therapy with phosphate binders. Even though
      calcium containing phosphate binders have been proven to be effective, they are reported to
      lead in certain patients to hypercalcaemia. This observational study therefore not only
      evaluates the efficacy of the phosphate binder OsvaRen® (containing calcium acetate and
      magnesium carbonate) but also the frequency of untoward events in daily practice as well as
      to the state of hyper-/ hypoparathyroidism as represented by serum iPTH values and the
      practice patterns used to adjust to and to fully exploit the qualities of the different
      available phosphate binders. In addition, the compensatory actions of the physicians, such as
      adaptation of the dialysate calcium or the combination with non-calcium containing phosphate
      binders, are going to be monitored. In order to receive additional safety data in the context
      of daily practice, the frequency of untoward events related to the treatment will be
      documented and analysed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
  </study_design_info>
  <primary_outcome>
    <measure>Serum phosphorus</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse drug reactions</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">324</enrollment>
  <condition>Hyperphosphataemia</condition>
  <condition>ESRD</condition>
  <arm_group>
    <arm_group_label>OsvaRen treatment</arm_group_label>
    <description>Dialysis patients on OsvaRen treatment</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Dialysis patients (HD, HDF, or PD) being treated with OsvaRen for hyperphosphataemia
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years

          -  Signed Informed Consent

          -  Patient on maintenance haemodialysis, online haemodiafiltration, or peritoneal
             dialysis at the time of OsvaRen® prescription

          -  Patients being treated with OsvaRen® for up to 6 months at the day of inclusion

        Exclusion Criteria:

          -  Prior participation in this observational study

          -  Use of OsvaRen® for purposes other than those indicated in the Summary of Product
             Characteristics (SmPC) / package leaflet
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Helmut Geiger, MD, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Frankfurt, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Regionshospitalet Holstebro</name>
      <address>
        <city>Holstebro</city>
        <zip>7500</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nykøbing Falster Sygehus</name>
      <address>
        <city>Nykobing</city>
        <zip>4800</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roskilde Sygehus</name>
      <address>
        <city>Roskilde</city>
        <zip>4000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Viborg Sygehus</name>
      <address>
        <city>Viborg</city>
        <zip>8800</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dialysezentrum</name>
      <address>
        <city>Aachen</city>
        <zip>52066</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dialysezentrum</name>
      <address>
        <city>Alsfeld</city>
        <zip>36304</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dialyszentrum/Gemeinschaftspraxis</name>
      <address>
        <city>Augsburg</city>
        <zip>86157</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nephrologicum Lausitz</name>
      <address>
        <city>Cottbus</city>
        <zip>03046</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Studienzentrum Karlstraße</name>
      <address>
        <city>Dusseldorf</city>
        <zip>40210</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dialyse am Lichtbogen</name>
      <address>
        <city>Essen</city>
        <zip>45141</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diakonissenkrankenhaus Flensburg</name>
      <address>
        <city>Flensburg</city>
        <zip>24939</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PHV-Dialysezentrum Goslar</name>
      <address>
        <city>Goslar</city>
        <zip>38642</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zentrum für Nieren-, Hochdruck- und Stoffwechselerkrankungen</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Nephrologie/Dialyse</name>
      <address>
        <city>Hoyerswerda</city>
        <zip>02977</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Internistische Schwerpunktpraxis Gastroenterologie / Nephrologie</name>
      <address>
        <city>Kaiserslautern</city>
        <zip>67655</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PHV Dialysezentrum Kiel</name>
      <address>
        <city>Kiel</city>
        <zip>24106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Dialyse</name>
      <address>
        <city>Magdeburg</city>
        <zip>39124</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dialysezentrum Pforzheim</name>
      <address>
        <city>Pforzheim</city>
        <zip>75179</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Infanta Leonor</name>
      <address>
        <city>Madrid</city>
        <zip>28032</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Ourense</name>
      <address>
        <city>Ourense</city>
        <zip>32005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marqués de Valdecilla</name>
      <address>
        <city>Santander</city>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Birmingham Heartlands Hospital</name>
      <address>
        <city>Birmingham</city>
        <zip>B95SS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Health and Social Care Trust</name>
      <address>
        <city>Londonderry</city>
        <zip>BT476SB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Shrewsbury Hospital</name>
      <address>
        <city>Shrewsbury</city>
        <zip>SY3 8XQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>de Francisco AL, Leidig M, Covic AC, Ketteler M, Benedyk-Lorens E, Mircescu GM, Scholz C, Ponce P, Passlick-Deetjen J. Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability. Nephrol Dial Transplant. 2010 Nov;25(11):3707-17. doi: 10.1093/ndt/gfq292. Epub 2010 Jun 7.</citation>
    <PMID>20530499</PMID>
  </reference>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 26, 2011</study_first_submitted>
  <study_first_submitted_qc>August 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2011</study_first_posted>
  <last_update_submitted>March 5, 2015</last_update_submitted>
  <last_update_submitted_qc>March 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperphosphatemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

